Voluntary scheme for branded medicines: payment percentage for 2020

AI Summary

This regulatory update details the 2020 financial requirements under the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS). The agreement, managed by the UK Department of Health and Social Care (DHSC) in partnership with the Association of the British Pharmaceutical Industry (ABPI), serves as the primary regulatory framework for managing the costs of branded medications within the NHS. While this specific document does not detail a site inspection or identify specific company violations, it establishes the mandatory 5.9% payment percentage for the year 2020. This percentage is a calculated mechanism designed to ensure that the total growth of the branded medicine bill remains within the agreed annual caps. The primary goal of this framework is to secure the best value for public spending while accelerating patient access to breakthrough clinical treatments. For pharmaceutical companies operating within the UK, the required action is to apply this 5.9% rate to their eligible sales of branded medicines and remit the corresponding funds to the DHSC. This ensures compliance with the voluntary scheme, which offers a more collaborative alternative to the statutory pricing regulations. By adhering to these financial requirements, companies contribute to a sustainable ecosystem that supports both industrial innovation and the clinical needs of the health service. The document provides transparency on the methodology used to derive this percentage, ensuring that all member companies understand the fiscal expectations for the upcoming period.